News
Latest News
"This committee has heard how this bill would marginalize an almost endless spectrum of Americans, but I fear we have not listened. Today, as we recall who this bill will harm and how, I note it’s not too late to show courage. Everyone on this dais can listen sincerely, take heart and oppose legislation based in political theory, not scientific reality. If my Democrat colleagues do advance this misguided bill, they must admit this legislative win creates millions of losers. Intellectual honesty requires us to count the cost of H.R. 5."
"Democrats have ignored the reality of the Mueller investigation . . . I implore you to stop bullying an attorney general who has conducted himself in an exemplary manner. Examine the report, ask earnest questions and heed the pleas of hardworking Americans who understand that our time is better spent making progress than chasing ghosts."
"Due to the lack of transparency, these price concessions are often withheld from patients and payers, increasing PBM profits while failing to decrease drug costs. H.R. 2376, the Prescription Pricing for the People Act of 2019, directs the FTC to review and report on PBMs' anticompetitive behaviors and other issues affecting competition in the pharmaceutical supply chain as a whole."
". . . for too long, drug manufacturers have been allowed to game the system by submitting numerous or baseless, bogus petitions simply so the FDA will delay competing manufacturers’ approvals. . . . The Stop STALLING Act is sound, bipartisan legislation that promises to stop this problem for good."
". . . if the branded manufacturer denies the provision of samples, it can delay its competitor’s approval and prop up its own drug’s high costs. This should not be happening. . . . The CREATES Act will prevent this kind of gaming and make sure that generic and biosimilar manufacturers can gain samples to complete testing and win FDA approvals."
"The Preserve Access to Affordable Generics and Biosimilars Act would . . . accelerate the lowering of prescription drug prices in America. . . . [and] prevent anticompetitive settlements that line drug company pockets while consumers pay the bill."
“The Prescription Pricing for the People Act of 2019 would shed light on how PBMs are affecting prescription costs and patient choice. This would support Congress as it crafts evidence-based solutions to address the anticompetitive role PBMs play as pharmaceutical costs continue to rise.”